uniQure NV (QURE)
25.28
+0.77
(+3.14%)
USD |
NASDAQ |
Sep 30, 10:15
uniQure Enterprise Value : 1.441B for Sept. 29, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 29, 2026 | 1.441B |
| September 28, 2026 | 2.454B |
| September 25, 2026 | 2.393B |
| September 24, 2026 | 2.399B |
| September 23, 2026 | 2.707B |
| September 22, 2026 | 2.881B |
| September 21, 2026 | 2.814B |
| September 18, 2026 | 2.793B |
| September 17, 2026 | 2.799B |
| September 16, 2026 | 2.688B |
| September 15, 2026 | 2.730B |
| September 14, 2026 | 2.857B |
| September 11, 2026 | 2.828B |
| September 10, 2026 | 2.825B |
| September 09, 2026 | 2.931B |
| September 08, 2026 | 2.909B |
| September 04, 2026 | 2.827B |
| September 03, 2026 | 2.852B |
| September 02, 2026 | 2.947B |
| September 01, 2026 | 3.060B |
| August 31, 2026 | 3.117B |
| August 28, 2026 | 3.120B |
| August 27, 2026 | 3.178B |
| August 26, 2026 | 3.274B |
| August 25, 2026 | 3.281B |
| Date | Value |
|---|---|
| August 24, 2026 | 3.032B |
| August 21, 2026 | 3.096B |
| August 20, 2026 | 3.132B |
| August 19, 2026 | 3.123B |
| August 18, 2026 | 3.027B |
| August 17, 2026 | 3.068B |
| August 14, 2026 | 3.113B |
| August 13, 2026 | 3.005B |
| August 12, 2026 | 2.871B |
| August 11, 2026 | 2.862B |
| August 10, 2026 | 2.935B |
| August 07, 2026 | 2.960B |
| August 06, 2026 | 2.887B |
| August 05, 2026 | 2.809B |
| August 04, 2026 | 2.770B |
| August 03, 2026 | 2.797B |
| July 31, 2026 | 2.767B |
| July 30, 2026 | 2.667B |
| July 29, 2026 | 2.520B |
| July 28, 2026 | 2.284B |
| July 27, 2026 | 2.391B |
| July 24, 2026 | 2.444B |
| July 23, 2026 | 2.476B |
| July 22, 2026 | 2.542B |
| July 21, 2026 | 2.521B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Kymera Therapeutics, Inc. | 8.537B |
| Sarepta Therapeutics, Inc. | 2.226B |
| Twist Bioscience Corp. | 11.59B |
| GRAIL, Inc. | 5.330B |
| Arrowhead Pharmaceuticals, Inc. | 9.125B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -81.06M |
| Revenue (Quarterly) | 5.841M |
| Total Expenses (Quarterly) | 86.90M |
| EPS Diluted (Quarterly) | -1.224 |
| Gross Profit Margin (Quarterly) | 10.00% |
| Profit Margin (Quarterly) | -1.39K% |
| Earnings Yield | -16.01% |
| Normalized Earnings Yield | -15.89 |